DiscoveRx Corporation Unveils a New Strategic Direction

DiscoveRx Corporation, a leading provider of GPCR and Kinase assays, today announced its new strategic vision to focus on expanding its development of a series of innovative biochemical and cell based assays. The Company’s new cell based assay platform is called PathHunter™. This announcement immediately follows the recent penning of a global distribution agreement with GE Healthcare. That exclusive agreement provided GE with expanded access to the DiscoveRx HitHunter™ range of products. HitHunter™, and especially the cAMP product family, is a well adopted portfolio in the drug discovery screening community.

“With GE Healthcare taking on a leadership role in global marketing and sales of our flagship HitHunter product range, DiscoveRx can focus on developing and commercializing key products for kinases and cell based assays. For instance, PathHunter™ has completely revolutionized the way drug discovery researchers conduct high throughput cell based assays and the market is requesting more assays for key target classes” said Dr. Pyare Khanna, CEO of DiscoveRx. “It is gratifying to see the rapid adoption of our new PathHunter and kinase assays by the drug discovery community and DiscoveRx is committed to launch additional assays and services in near future”.

The PathHunter cell based assay platform from DiscoveRx is a revolutionary screening technology that utilizes a unique protein tag, called ProLabel™, to study cell signaling events based on protein translocation, secretion, degradation and trafficking. Several leading pharmaceutical and biotech screening groups have already adopted PathHunter based protein translocation assays. These novel cellular assays study protein function without the need for imaging or expensive reporter technologies. For a complete list of PathHunter biosensor cell lines, vectors and screening reagents, please visit the article webpage or contact your local technical sales specialist.